Loading patent…
AssigneeGlaxoSmithKline Intellectual Property Development Limited
InventorsYao-Bin LIU, Patrick Mayes, Radha Shah Parmar
Estimating the term…
The present invention relates to an ICOS binding protein or antigen binding portion thereof that is an agonist to human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell; stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more of: SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and/or SEQ ID NO:6.
An ICOS binding protein or antigen binding portion thereof comprising a VH domain comprising an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO:7 and a VL domain comprising an amino acid sequence at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:8 wherein said ICOS binding protein specifically binds to human ICOS.
An ICOS binding protein or antigen binding portion thereof, wherein the ICOS binding protein or antigen binding portion thereof cross-competes for binding to human ICOS with a reference antibody or antigen binding portion thereof comprising a VH domain comprising the amino acid sequence set forth in SEQ ID NO:
Dependencies are inferred from the claim text.